Ozagrel Sodium Injection is not usually used for the prevention of cerebral thrombosis, but mainly for the treatment of the acute phase of thrombotic cerebral infarction. There is no evidence-based medical evidence that ozagrel sodium injection prevents cerebral thrombosis. Ozagrel Sodium Injection is a thromboxane synthase inhibitor, which can inhibit the production of thromboxane 2, thus acting as an anti-platelet aggregation and vasodilator. Ozagrel Sodium Injection can improve cerebral microcirculation, improve the symptoms of cerebral artery ischemia in cerebral thrombosis, especially for acute cerebral infarction accompanied by dyskinesia has obvious therapeutic effect. Adverse reactions of ozagrel sodium injection include gastrointestinal reactions and allergic reactions, such as nausea, vomiting, urticaria, rash, etc. Ozagrel Sodium Injection is contraindicated in patients with cerebral hemorrhage, severe cardiac, pulmonary, hepatic, and renal insufficiency, as well as blood disorders. Prevention of cerebral thrombosis can use other classic antiplatelet drugs, such as aspirin, clopidogrel, etc., but all of the above drugs need to be taken under the guidance of a doctor, avoid self-medication.